AGENTS USEFUL IN TREATING INFLAMMATORY BOWEL DISEASE
    26.
    发明申请
    AGENTS USEFUL IN TREATING INFLAMMATORY BOWEL DISEASE 审中-公开
    有助于治疗炎症性皮肤病的药物

    公开(公告)号:WO2006070012A1

    公开(公告)日:2006-07-06

    申请号:PCT/EP2005/057210

    申请日:2005-12-29

    CPC classification number: A61K31/00 A61K31/18

    Abstract: The invention relates to novel methods of preventing, treating, or ameliorating Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis and Crohn's disease, by administering compounds that are capable of inhibiting human neutrophil elastase (HNE), as well as to the use of said compounds for preparing pharmaceutical compositions for preventing, treating, or ameliorating IBD. Furthermore, the invention relates to pharmaceutical compositions comprising HNE inhibitors and further comprising one or more compounds known to be effective in treating IBD.

    Abstract translation: 本发明涉及通过施用能够抑制人嗜中性粒细胞弹性蛋白酶(HNE)的化合物以及使用以下方法来预防,治疗或改善炎性肠病(IBD),特别是溃疡性结肠炎和克罗恩病的新方法 所述用于制备用于预防,治疗或改善IBD的药物组合物的化合物。 此外,本发明涉及包含HNE抑制剂并进一步包含已知有效治疗IBD的一种或多种化合物的药物组合物。

    METHODS AND AGENTS USEFUL IN TREATING CONDITIONS CHARACTERIZED BY MUCUS HYPERPRODUCTION/HYPERSECRETION
    27.
    发明申请
    METHODS AND AGENTS USEFUL IN TREATING CONDITIONS CHARACTERIZED BY MUCUS HYPERPRODUCTION/HYPERSECRETION 审中-公开
    用于处理由MUCUS HYPERPRODUCTION / HYPERSECRETION表征的条件的方法和代理

    公开(公告)号:WO2006061418A2

    公开(公告)日:2006-06-15

    申请号:PCT/EP2005/056610

    申请日:2005-12-08

    CPC classification number: C12N15/113 C12N2310/111 C12N2310/14 C12N2310/53

    Abstract: The present invention inter alia relates to gene silencing of the Agr2 gene by short interfering RNAs. Moreover, in view of the involvement of Agr2 in mucus production, the invention also relates to pharmaceutical compositions useful as medicaments in methods for the prevention, amelioration or treatment of medical conditions associated with mucus hyperproduction / hypersecretion, particularly in the respiratory tract. Novel siRNAs which are useful in the above methods, and novel pharmaceutical compositions are likewise provided. The invention further relates to screening methods for additional siRNAs capable of silencing the expression of the Agr2 gene.

    Abstract translation: 本发明尤其涉及通过短干扰RNA对Agr2基因的基因沉默。 此外,鉴于Agr2参与粘液生产,本发明还涉及用作预防,改善或治疗与粘液生产过度/分泌过多相关的医学病症,特别是在呼吸道中的药物的药物中的药物组合物。 可用于上述方法的新型siRNA以及新的药物组合物同样被提供。 本发明还涉及能够沉默Agr2基因表达的其它siRNA的筛选方法。

Patent Agency Ranking